

Haematologica
HAEMATOL/2019/230011
Version 4

Fractures and survival in multiple myeloma: results from a
population-based study

Sigrun Thorsteinsdottir, Gauti Gislason, Thor Aspelund, Ingigerdur Sverrisdottir, Ola Landgren, Ingemar Turesson, Magnus Björkholm, and Sigurður Y. Kristinsson

Disclosures: This work was supported by grants from the University of Iceland Research Fund, Icelandic Centre for Research (RANNIS), Landspítali University Hospital Research Fund, Karolinska Institutet Foundations, Marie Curie CIG, and the Cancer Society in Stockholm. Disclosures for O.L.: Grant support: NIH, FDA, MMRF, IMF, LLS, Perelman Family Foundation, Rising Tides Foundation, Amgen, Celgene, Janssen, Takeda, Glenmark, Seattle Genetics, Karyopharm. Honoraria/ad boards: Adaptive, Amgen, Binding Site, BMS, Celgene, Cellectis, Glenmark, Janssen, Juno, Pfizer. Independent Data Monitoring Committee (IDMC): Takeda, Merck, Janssen. All other authors declare no competing financial interests.

Contributions: S.T. and S.Y.K. designed the research. S.T., G.G., I.S.S. and T.A. analyzed the data. All authors contributed to interpretation of the data analysis. S.Y.K., M.B., I.T. and O.L. provided the data. S.T. and S.Y.K. wrote the manuscript and all authors commented on the content and approved the final version.